{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T21:55:03Z","timestamp":1785189303777,"version":"3.55.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["NSFC 81670018"],"award-info":[{"award-number":["NSFC 81670018"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Key project from Chinese Ministry of Science and Technology","award":["2016YFA0101300"],"award-info":[{"award-number":["2016YFA0101300"]}]},{"name":"Science & Technology department of Sichuan Province","award":["22ZDZX0014 and 2020YFS0105"],"award-info":[{"award-number":["22ZDZX0014 and 2020YFS0105"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>The therapeutic effect of umbilical cord-derived mesenchymal stem cells (hUC-MSCs) in combination with pirfenidone (PFD) on pulmonary fibrosis in mice and its possible mechanism were investigated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>C57BL\/6 mice were randomly divided into six groups: control group, model group, P<jats:sub>10<\/jats:sub> group, P<jats:sub>30<\/jats:sub> group, P<jats:sub>100<\/jats:sub> group, and P<jats:sub>300<\/jats:sub> group. Modeled by tracheal intubation with 3\u00a0mg\/kg bleomycin drip, each dose of PFD was administered daily by gavage from day 7 onwards. The mice were observed continuously for 21\u00a0days and survival was recorded. Lung tissues were collected on day 21, and hematoxylin\u2013eosin (HE) and Masson staining were performed to assess morphological changes and collagen deposition in the lungs. Collagen content was measured by the Sircol method, and fibrosis marker levels were detected by PCR and Western blot. Another batch of C57BL\/6 mice was then randomly divided into five groups: hUC-MSC control group, model group, P<jats:sub>100<\/jats:sub> group, hUC-MSC treatment group, and hUC-MSCs\u2009+\u2009P<jats:sub>30<\/jats:sub> group. On day 7, 5\u2009\u00d7\u200910<jats:sup>5<\/jats:sup> hUC-MSCs were injected into the tail vein, the mice were administered PFD gavage daily from day 7 onwards, and their survival was recorded. Lung tissues were collected on day 21 to detect pathological changes, the collagen content, and the expression of regulator of G protein signaling 2 (RGS2). Pulmonary myofibroblasts (MFBs) were divided into an MFB group and an MFB\u2009+\u2009hUC-MSCs group; different doses of PFD were administered to each group, and the levels of RGS2, intracellular Ca<jats:sup>2+<\/jats:sup>, and fibrosis markers were recorded for each group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Compared with other PFD group doses, the P<jats:sub>100<\/jats:sub> group had significantly improved mouse survival and lung pathology and significantly reduced collagen and fibrosis marker levels (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). The hUC-MSCs\u2009+\u2009P<jats:sub>30<\/jats:sub> group had significantly improved mouse survival and lung pathology, significantly reduced collagen content and fibrosis marker levels (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05), and the efficacy was better than that of the P<jats:sub>100<\/jats:sub> and hUC-MSCs groups (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). RGS2 expression was significantly higher in the MSCs\u2009+\u2009P<jats:sub>30<\/jats:sub> group compared with the P<jats:sub>100<\/jats:sub> and hUC-MSCs groups (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). PFD increased RGS2 expression in MFBs (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05) in a dose-dependent manner. Compared with PFD and hUC-MSCs treatment alone, combination of hUC-MSCs and PFD increased RGS2 protein levels, significantly decreased intracellular Ca<jats:sup>2+<\/jats:sup> concentration, and significantly reduced fibrosis markers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The findings suggest that hUC-MSCs combined with low-dose PFD have a therapeutic effect better than that of the two treatments used separately. Its effect on attenuating bleomycin-induced pulmonary fibrosis in mice is related to the increase of RGS2.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12931-022-02192-6","type":"journal-article","created":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T10:02:24Z","timestamp":1664618544000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Human umbilical cord mesenchymal stem cells combined with pirfenidone upregulates the expression of RGS2 in the pulmonary fibrosis in mice"],"prefix":"10.1186","volume":"23","author":[{"given":"Xian","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Gou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ou","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijun","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanmin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,1]]},"reference":[{"issue":"2","key":"2192_CR1","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","volume":"192","author":"G Raghu","year":"2015","unstructured":"Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, et al. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192(2):e3\u201319.","journal-title":"Am J Respir Crit Care Med"},{"key":"2192_CR2","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/S2213-2600(14)70101-8","volume":"2","author":"G Raghu","year":"2014","unstructured":"Raghu G, Chen SY, Yeh WS, Maroni B, Li Q, Lee YC, et al. Idiopathic pulmonary fibrosis in US medicare beneficiaries aged 65 years and older: incidence, prevalence and survival, 2001\u201311. Lancet Respir Med. 2014;2:566\u201372.","journal-title":"Lancet Respir Med"},{"issue":"3","key":"2192_CR3","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1183\/09031936.00185114","volume":"46","author":"J Hutchinson","year":"2015","unstructured":"Hutchinson J, Fogarty A, Hubbard R, McKeever T. Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J. 2015;46(3):795\u2013806.","journal-title":"Eur Respir J"},{"key":"2192_CR4","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","volume":"37","author":"TE King Jr","year":"2014","unstructured":"King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A Phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;37:2083\u201392.","journal-title":"N Engl J Med"},{"key":"2192_CR5","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","volume":"377","author":"PW Noble","year":"2011","unstructured":"Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377:1760\u20139.","journal-title":"Lancet"},{"issue":"3","key":"2192_CR6","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3727\/096368915X686841","volume":"24","author":"DC Ding","year":"2015","unstructured":"Ding DC, Chang YH, Shyu WC, Lin SZ. Human umbilical cord mesenchymal stem cells: a new era for stem cell therapy. Cell Transplant. 2015;24(3):339\u201347.","journal-title":"Cell Transplant"},{"issue":"3","key":"2192_CR7","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.stem.2008.07.003","volume":"3","author":"M Crisan","year":"2008","unstructured":"Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS, et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell. 2008;3(3):301\u201313.","journal-title":"Cell Stem Cell"},{"key":"2192_CR8","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev-cellbio-100913-013132","volume":"30","author":"P Bianco","year":"2014","unstructured":"Bianco P. \u201cMesenchymal\u201d stem cells. Annu Rev Cell Dev Biol. 2014;30:677\u2013704.","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"5","key":"2192_CR9","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/j.jpeds.2013.12.011","volume":"64","author":"YS Chang","year":"2014","unstructured":"Chang YS, Ahn SY, Yoo HS, Sung SI, Choi SJ, Oh WI, et al. Mesenchymal stem cells for bronchopulmonary dysplasia: Phase 1 dose-escalation clinical trial. J Pediatr. 2014;64(5):966\u201372.","journal-title":"J Pediatr"},{"issue":"1","key":"2192_CR10","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41392-020-00286-5","volume":"5","author":"M Fanping","year":"2020","unstructured":"Fanping M, Ruonan X, Siyu W, Zhe X, Chao Z, Yuanyuan L, et al. Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial. Signal Transduct Target Therapy. 2020;5(1):172.","journal-title":"Signal Transduct Target Therapy."},{"issue":"1","key":"2192_CR11","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/S2213-2600(14)70291-7","volume":"3","author":"JG Wilson","year":"2015","unstructured":"Wilson JG, Liu KD, Zhuo H, Caballero L, McMillan M, Fang X, et al. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med. 2015;3(1):24\u201332.","journal-title":"Lancet Respir Med"},{"key":"2192_CR12","doi-asserted-by":"publisher","first-page":"192","DOI":"10.15283\/ijsc16041","volume":"9","author":"M Reddy","year":"2016","unstructured":"Reddy M, Fonseca L, Gowda S, Chougule B, Hari A, Totey S. Human adipose-derived mesenchymal stem cells attenuate early stage of bleomycin induced pulmonary fibrosis: comparison with pirfenidone. Int J Stem Cells. 2016;9:192\u2013206.","journal-title":"Int J Stem Cells"},{"key":"2192_CR13","doi-asserted-by":"publisher","first-page":"303","DOI":"10.2353\/ajpath.2009.080629","volume":"175","author":"Y Moodley","year":"2009","unstructured":"Moodley Y, Atienza D, Manuelpillai U, Samuel CS, Tchongue J, Ilancheran S, et al. Human umbilical cord mesenchymal stem cells reduce fibrosis of bleomycin induced lung injury. Am J Pathol. 2009;175:303\u201313.","journal-title":"Am J Pathol"},{"key":"2192_CR14","unstructured":"Danyi P. Combonation of human umbilical cord mesenchymal stem cells and nintedanib ameliorates mice pulmonary fibrosis induced by blemycin. Chongqing, Chongqing Medical University, 2017."},{"issue":"6","key":"2192_CR15","first-page":"2321","volume":"21","author":"Z Hong","year":"2020","unstructured":"Hong Z, Chundi L, Lina L, Junying L, Yinghui G, Kun M, et al. Baicalin alleviates bleomycin-induced pulmonary fibrosis and fibroblast proliferation in rats via the PI3K\/AKT signaling pathway. Mol Med Rep. 2020;21(6):2321\u201334.","journal-title":"Mol Med Rep"},{"key":"2192_CR16","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13223-018-0266-5","volume":"14","author":"G Tresa","year":"2018","unstructured":"Tresa G, Mainak C, Mark AG, Robert N. A bronchoprotective role for Rgs2 in a murine model of lipopolysaccharide-induced airways inflammation. Allergy Asthma Clin Immunol. 2018;14:40.","journal-title":"Allergy Asthma Clin Immunol"},{"key":"2192_CR17","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1165\/rcmb.2014-0319OC","volume":"53","author":"H Jiang","year":"2015","unstructured":"Jiang H, Xie Y, Abel PW, Wolff DW, Toews ML, Panettieri RA Jr, et al. RGS2 repression exacerbates airway hyperresponsiveness and remodeling in asthma. Am J Respir Cell Mol Biol. 2015;53:42\u20139.","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"9","key":"2192_CR18","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1016\/j.bbadis.2014.06.022","volume":"1842","author":"HS Jang","year":"2014","unstructured":"Jang HS, Kim JI, Noh M, Rhee MH, Park KM. Regulator of G protein signaling 2 (RGS2) deficiency accelerates the progression of kidney fibrosis. Biochim Biophys Acta. 2014;1842(9):1733\u201341.","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"2192_CR19","doi-asserted-by":"publisher","first-page":"H147","DOI":"10.1152\/ajpheart.00026.2011","volume":"301","author":"Z Peng","year":"2011","unstructured":"Peng Z, Jialin S, Michelle EK, Angel EM, Cindy P, Ulrike M. Regulator of G protein signaling 2 is a functionally important negative regulator of angiotensin II-induced cardiac fibroblast responses. Am J Physiol Heart Circ Physiol. 2011;301(1):H147\u201356.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2192_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-016-0418-4","author":"Y Xie","year":"2016","unstructured":"Xie Y, Jiang H, Zhang Q, Mehrotra S, Abel PW, Toews ML, et al. Upregulation of RGS2: a new mechanism for pirfenidone amelioration of pulmonary fibrosis. Respir Res. 2016. https:\/\/doi.org\/10.1186\/s12931-016-0418-4.","journal-title":"Respir Res"},{"key":"2192_CR21","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1136\/jcp.41.4.467","volume":"41","author":"T Ashcroft","year":"1988","unstructured":"Ashcroft T, Simpson JM, Timbrell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol. 1988;41:467\u201370.","journal-title":"J Clin Pathol"},{"key":"2192_CR22","doi-asserted-by":"publisher","first-page":"39889","DOI":"10.1038\/srep39889","volume":"7","author":"Z Hua","year":"2017","unstructured":"Hua Z, Yi X, Yunqiu X, Rong Z, Daiyin T, Ting W, et al. Therapeutic effects of human umbilical cord-derived mesenchymal stem cells in acute lung injury mice. Sci Rep. 2017;7:39889.","journal-title":"Sci Rep"},{"key":"2192_CR23","unstructured":"Zhang Y. The investigation of human umbilical cord mesenchymal stem cells on pulmonary fibrosis mice models. Chongqing, Chongqing Medical University. 2015."},{"key":"2192_CR24","doi-asserted-by":"publisher","first-page":"5811","DOI":"10.1074\/jbc.M507871200","volume":"281","author":"W Zhang","year":"2006","unstructured":"Zhang W, Anger T, Su J, Hao J, Xu X, Zhu M, et al. Selective loss of fine tuning of Gq\/11 signaling by RGS2 protein exacerbates cardiomyocyte hypertrophy. J Biol Chem. 2006;281:5811\u201320.","journal-title":"J Biol Chem"},{"key":"2192_CR25","doi-asserted-by":"crossref","unstructured":"Fernandez IE, Eickelberg O. New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis. Lancet. 2012;18;380(9842):680\u20138.","DOI":"10.1016\/S0140-6736(12)61144-1"},{"issue":"1","key":"2192_CR26","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1378\/chest.130.1.22","volume":"130","author":"N Enomoto","year":"2006","unstructured":"Enomoto N, Suda T, Kato M, Kaida Y, Nakamura Y, Imokawa S, et al. Quantitative analysis of fibroblastic foci in usual interstitial pneumonia. Chest. 2006;130(1):22\u20139.","journal-title":"Chest"},{"issue":"13","key":"2192_CR27","doi-asserted-by":"publisher","first-page":"6829","DOI":"10.3390\/ijms22136829","volume":"22","author":"WK Yu","year":"2021","unstructured":"Yu WK, Hwang WL, Wang YC, Tsai CC, Wei YH. Curcumin suppresses TGF-\u03b21-induced myofibroblast differentiation and attenuates angiogenic activity of orbital fibroblasts. Int J Mol Sci. 2021;22(13):6829.","journal-title":"Int J Mol Sci"},{"key":"2192_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.649476","volume":"11","author":"QJ Kang","year":"2021","unstructured":"Kang QJ, Peng XD, Li XS, Hu DH, Wen GX, Wei ZQ, et al. Calcium channel protein ORAI1 mediates TGF-\u03b2 induced epithelial-to-mesenchymal transition in colorectal cancer cells. Front Oncol. 2021;11: 649476.","journal-title":"Front Oncol"},{"key":"2192_CR29","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.ejphar.2008.06.046","volume":"590","author":"H Oku","year":"2008","unstructured":"Oku H, Shimizu T, Kawabata T, Nagira M, Hikita I, Ueyama A, et al. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol. 2008;590:400\u20138.","journal-title":"Eur J Pharmacol"},{"key":"2192_CR30","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1164\/rccm.200404-571OC","volume":"171","author":"A Azuma","year":"2005","unstructured":"Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005;171:1040\u20137.","journal-title":"Am J Respir Crit Care Med"},{"key":"2192_CR31","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s12325-015-0225-1","volume":"32","author":"MS Wijsenbeek","year":"2015","unstructured":"Wijsenbeek MS, Grutters JC, Wuyts WA. Early experience of pirfenidone in daily clinical practice in Belgium and the Netherlands: a retrospective cohort analysis. Adv Therapy. 2015;32:691\u2013704.","journal-title":"Adv Therapy"},{"issue":"7","key":"2192_CR32","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/nm.2807","volume":"18","author":"AW Thomas","year":"2012","unstructured":"Thomas AW, Thirumalai RR. Mechanisms of fbrosis: therapeutic translation for fibrotic disease. Nat Med. 2012;18(7):1028\u201340.","journal-title":"Nat Med"},{"key":"2192_CR33","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/scrt513","volume":"5","author":"A Gazdhar","year":"2014","unstructured":"Gazdhar A, Grad I, Tam\u00f2 L, Gugger M, Feki A, Geiser T. The secretome of induced pluripotent stem cells reduces lung fibrosis in part by hepatocyte growth factor. Stem Cell Res Ther. 2014;5:123.","journal-title":"Stem Cell Res Ther"},{"issue":"10","key":"2192_CR34","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1002\/jcb.23216","volume":"112","author":"E Mezey","year":"2011","unstructured":"Mezey E. The therapeutic potential of bone-marrow-derived stromal cells. J Cell Biochem. 2011;112(10):2683\u20137.","journal-title":"J Cell Biochem"},{"key":"2192_CR35","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.ejphar.2008.06.046","volume":"20","author":"H Oku","year":"2008","unstructured":"Oku H, Shimizu T, Kawabata T, Nagira M, Hikita I, Ueyama A, et al. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced pulmonary fibrosis. Eur J Pharmacol. 2008;20:400\u20138.","journal-title":"Eur J Pharmacol"},{"key":"2192_CR36","first-page":"2","volume":"10","author":"M Myllarniemi","year":"2015","unstructured":"Myllarniemi M, Kaarteenaho R. Pharmacological treatment of idiopathic pulmonary fibrosis preclinical and clinical studies of pirfenidone, nintedanib, and N-acetylcysteine. Eur Clin Respir J. 2015;10:2.","journal-title":"Eur Clin Respir J"},{"issue":"2","key":"2192_CR37","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1080\/07435800.2022.2036752","volume":"47","author":"DB Alsafadi","year":"2022","unstructured":"Alsafadi DB, Abdullah MS, Bawadi R, Ahram M. The association of RGS2 and slug in the androgen-induced acquisition of mesenchymal features of breast MDA-MB-453 cancer cells. Endocr Res. 2022;47(2):64\u201379.","journal-title":"Endocr Res"},{"key":"2192_CR38","doi-asserted-by":"publisher","first-page":"21248","DOI":"10.1074\/jbc.M312407200","volume":"279","author":"LS Bernstein","year":"2004","unstructured":"Bernstein LS, Ramineni S, Hague C, Cladman W, Chidiac P, Levey AI, et al. RGS2 binds directly and selectively to the M1 muscarinic acetylcholine receptor third intracellular loop to modulate Gq\/11alpha signaling. J Biol Chem. 2004;279:21248\u201356.","journal-title":"J Biol Chem"},{"key":"2192_CR39","doi-asserted-by":"publisher","first-page":"14389","DOI":"10.1073\/pnas.94.26.14389","volume":"94","author":"SP Heximer","year":"2008","unstructured":"Heximer SP, Watson N, Linder ME, Blumer KJ, Hepler JR. RGS2\/G0S8 is a selective inhibitor of G\u03b1q function. Proc Natl Acad Sci USA. 2008;94:14389\u201393.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2192_CR40","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0192-0561(99)00056-9","volume":"21","author":"I Shahar","year":"1999","unstructured":"Shahar I, Fireman E, Topilsky M, Grief J, Schwarz Y, Kivity S, et al. Effect of endothelin-1 on alpha-smooth muscle actin expression and on alveolar fibroblasts proliferation in interstitial lung diseases. Int J Immunopharmacol. 1999;21:759-75.26.","journal-title":"Int J Immunopharmacol."},{"key":"2192_CR41","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/nm1685","volume":"14","author":"AM Tager","year":"2008","unstructured":"Tager AM, LaCamera P, Shea BS, Campanella GS, Selman M, Zhao Z, et al. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med. 2008;14:45\u201354.","journal-title":"Nat Med"},{"key":"2192_CR42","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1136\/thx.2009.134353","volume":"65","author":"M K\u00f6nigshoff","year":"2010","unstructured":"K\u00f6nigshoff M, Dumitrascu R, Udalov S, Amarie OV, Reiter R, Grimminger F, et al. Increased expression of 5-hydroxytryptamine2A\/B receptors in idiopathic pulmonary fibrosis: a rationale for therapeutic intervention. Thorax. 2010;65:949\u201355.","journal-title":"Thorax"},{"key":"2192_CR43","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1136\/thoraxjnl-2013-204367","volume":"69","author":"RJ Jos\u00e9","year":"2014","unstructured":"Jos\u00e9 RJ, Williams AE, Chambers RC. Proteinase-activated receptors in fibroproliferative lung disease. Thorax. 2014;69:190\u20132.","journal-title":"Thorax"},{"key":"2192_CR44","doi-asserted-by":"publisher","first-page":"45184","DOI":"10.1074\/jbc.M106441200","volume":"276","author":"GS Bogatkevich","year":"2001","unstructured":"Bogatkevich GS, Tourkina E, Silver RM, Ludwicka-Bradley A. Thrombin differentiates normal lung fibroblasts to a myofibroblast phenotype via the proteolytically activated receptor-1 and a protein kinase C-dependent pathway. J Biol Chem. 2001;276:45184\u201392.","journal-title":"J Biol Chem"},{"key":"2192_CR45","doi-asserted-by":"publisher","first-page":"C1141","DOI":"10.1152\/ajpcell.1995.268.5.C1141","volume":"268","author":"BG Bachhuber","year":"1995","unstructured":"Bachhuber BG, Sarembock IJ, Gimple LW, McNamara CA, Owens GK. Thrombin-induced mitogenesis in cultured aortic smooth muscle cells requires prolonged thrombin exposure. Am J Physiol. 1995;268:C1141\u20137.","journal-title":"Am J Physiol"},{"key":"2192_CR46","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1007\/s10517-007-0425-z","volume":"144","author":"J Ide","year":"2007","unstructured":"Ide J, Aoki T, Ishivata S, Glusa E, Strukova SM. Proteinase-activated receptor agonists stimulate the increase in intracellular Ca2+ in cardiomyocytes and proliferation of cardiac fibroblasts from chick embryos. Bull Exp Biol Med. 2007;144:760\u20133.","journal-title":"Bull Exp Biol Med"},{"issue":"10","key":"2192_CR47","doi-asserted-by":"publisher","first-page":"5546","DOI":"10.4049\/jimmunol.169.10.5546","volume":"169","author":"SR Vlahakis","year":"2002","unstructured":"Vlahakis SR, Villasis-Keever A, Gomez T, Vanegas M, Vlahakis N, Paya CV. G protein-coupled chemokine receptors induce both survival and apoptotic signaling pathways. J Immunol. 2002;169(10):5546\u201354.","journal-title":"J Immunol"},{"issue":"1","key":"2192_CR48","doi-asserted-by":"publisher","first-page":"L86","DOI":"10.1152\/ajplung.00132.2015","volume":"310","author":"CJ Winters","year":"2016","unstructured":"Winters CJ, Koval O, Murthy S, Allamargot C, Sebag SC, Paschke JD, et al. CaMKII inhibition in type II pneumocytes protects from bleomycin-induced pulmonary fibrosis by preventing Ca2+-dependent apoptosis. Am J Physiol Lung Cell Mol Physiol. 2016;310(1):L86-94.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"6","key":"2192_CR49","first-page":"2321","volume":"21","author":"H Zhao","year":"2020","unstructured":"Zhao H, Li CD, Li LN, Liu JY, Gao YH, Mu K. Baicalin alleviates bleomycin-induced pulmonary fibrosis and fibroblast proliferation in rats via the PI3K\/AKT signaling pathway. Mol Med Rep. 2020;21(6):2321\u201334.","journal-title":"Mol Med Rep"},{"issue":"2","key":"2192_CR50","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jdermsci.2021.07.005","volume":"103","author":"WL Hsu","year":"2021","unstructured":"Hsu WL, Hsieh YC, Yu HS, Yoshioka T, Wu CY. 2-Aminoethyl diphenylborinate inhibits bleomycin-induced skin and pulmonary fibrosis via interrupting intracellular Ca2+ regulation. J Dermatol Sci. 2021;103(2):101\u20138.","journal-title":"J Dermatol Sci"},{"key":"2192_CR51","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.cellsig.2003.11.006","volume":"16","author":"A Ghavami","year":"2004","unstructured":"Ghavami A, Hunt RA, Olsen MA, Zhang J, Smith DL, Kalgaonkar S, et al. Differential effects of regulator of G protein signaling (RGS) proteins on serotonin 5-HT1A, 5-HT2A, and dopamine D2 receptor-mediated signaling and adenylyl cyclase activity. Cell Signal. 2004;16:711\u201321.","journal-title":"Cell Signal"},{"issue":"2\u20133","key":"2192_CR52","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.toxlet.2010.03.009","volume":"195","author":"Q Li","year":"2010","unstructured":"Li Q, Turdi S, Thomas DP, Zhou TJ, Ren J. Intra-myocardial delivery of mesenchymal stem cells ameliorates left ventricular and cardiomyocyte contractile dysfunction following myocardial infarction. Toxicol Lett. 2010;195(2\u20133):119\u201326.","journal-title":"Toxicol Lett"},{"issue":"1","key":"2192_CR53","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.bbrc.2020.04.048","volume":"527","author":"LZ Wu","year":"2020","unstructured":"Wu LZ, Zhang GR, Guo CG, Pan YP. Intracellular Ca2+ signaling mediates IGF-1-induced osteogenic differentiation in bone marrow mesenchymal stem cells. Biochem Biophys Res Commun. 2020;527(1):200\u20136.","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-022-02192-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-022-02192-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-022-02192-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T22:02:44Z","timestamp":1664661764000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-022-02192-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,1]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2192"],"URL":"https:\/\/doi.org\/10.1186\/s12931-022-02192-6","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,1]]},"assertion":[{"value":"31 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No human participants, human data or human tissue involved in studies reported in this manuscript. All animal studies were approved by the Animal Ethics Committee of Chongqing Medical University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"270"}}